Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery - Related Studies

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

This study has been completed.

Study NCT00004895. Last updated on October 18, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Cancer-Related Problem/Condition
		Colorectal Cancer
		Extrahepatic Bile Duct Cancer
		Gastric Cancer
		Gastrointestinal Stromal Tumor
		Nausea and Vomiting
		Ovarian Cancer
		Pancreatic Cancer
		Peritoneal Cavity Cancer
		Small Intestine Cancer

2	Additional conditions recognized in this trial
		Bile Duct Neoplasms
		Colorectal Neoplasms
		Duodenal Neoplasms
		Gastrointestinal Stromal Tumors
		Ileal Neoplasms
		Intestinal Neoplasms
		Intestinal Obstruction
		Jejunal Neoplasms
		Ovarian Neoplasms
		Pancreatic Neoplasms
		Stomach Neoplasms
		Vomiting

3	More general conditions related to this trial
		Adnexal Diseases
		Bile Duct Diseases
		Biliary Tract Diseases
		Biliary Tract Neoplasms
		Colonic Diseases
		Digestive System Diseases
		Digestive System Neoplasms
		Duodenal Diseases
		Endocrine Gland Neoplasms
		Endocrine System Diseases
		Gastrointestinal Diseases
		Gastrointestinal Neoplasms
		Genital Diseases, Female
		Genital Neoplasms, Female
		Gonadal Disorders
		Ileal Diseases
		Intestinal Diseases
		Jejunal Diseases
		Neoplasms
		Neoplasms by Site
		Ovarian Diseases
		Pancreatic Diseases
		Rectal Diseases
		Signs and Symptoms
		Signs and Symptoms, Digestive
		Stomach Diseases
		Urogenital Neoplasms

4	Interventions listed in this trial
		octreotide acetate

5	Additional drug interventions recognized in this trial
		Octreotide

6	More general drug interventions related to this trial
		Antineoplastic Agents
		Antineoplastic Agents, Hormonal
		Gastrointestinal Agents
		Pharmacologic Actions
		Therapeutic Uses

7	Sponsors listed in this trial
		Robert H. Lurie Cancer Center
		National Cancer Institute (NCI)